Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 46, Issue 1, Pages 238-250Publisher
SPRINGER
DOI: 10.1007/s00259-018-4171-4
Keywords
Immunotherapy; Immune checkpoint inhibitors; Pseudoprogression; Hyperprogression; Immune-related side effects; Therapy response
Funding
- AIRC (Associazione Italiana per la Ricerca sul Cancro) [18923]
- National Health and Medical Research Council of Australia Practitioner Fellowship
Ask authors/readers for more resources
This paper follows the immunotherapy symposium held during the European Association of Nuclear Medicine (EANM) 2017 Annual Congress. The biological basis of the immune checkpoint inhibitors and the drugs most frequently used for the treatment of solid tumours are reviewed. The issues of pseudoprogression (frequency, timeline), hyperprogression and immune-related side effects are discussed, as well as their implications for patient management. A review of the recent literature on the use of FDG PET for assessment of immunotherapy is presented, and recommendations are provided for assessing tumour response and reporting immune-related side effects with FDG PET based on published data and experts' experience. Representative clinical cases are also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available